TY - JOUR
T1 - Is hypermethylation of SOX1 gene an independent prognostic marker in surgically resected non‑small cell lung cancer?
AU - Kontic, Milica
AU - Jovanovic, Dragana
AU - Kern, Izidor
AU - Nelson, Heather H.
AU - Bojic, Svetlana
AU - Ognjanovic, Miodrag
AU - Ognjanovic, SImona
N1 - Publisher Copyright:
© 2021 Journal of Cancer Research and Therapeutics.
PY - 2022/10
Y1 - 2022/10
N2 - Background: Promoter hypermethylation of tumor suppressor genes presents promising markers for lung cancer diagnosis and prognosis. The purpose of this study was to determine the association between the promoter hypermethylation of multiple genes and 5‑year survival rate in patients with Non‑small cell lung cancer (NSCLC). Materials and Methods: Primary tumor samples (n = 65), corresponding nonmalignant lung tissues (n = 65), and circulating blood were obtained from NSCLC patients who underwent curative surgery. Promoter methylation status in seven genes (RASSF1A, CDH13, MGMT, ESR1, DAPK, SOX1, and HOXA9) was quantified by using bisulfite pyrosequencing. Five‑year survival data were obtained by a clinician. Cox proportional hazards models were used to analyze the associations between gene methylation status and overall patient survival. Results: The 5‑year survival of the patients with SOX1 aberrant tumor methylation was found to be statistically significantly shorter than for those patients without aberrant tumor methylation (P = 0.01). This effect was independent of TNM stage. No significant survival differences were associated with aberrant methylation in other genes tested in either of the two tissue types. Conclusion: Our study shows that SOX1 promoter hypermethylation in NSCLC tumors is significantly associated with inferior survival, showing promise as a useful prognostic biomarker in patients with NSCLC.
AB - Background: Promoter hypermethylation of tumor suppressor genes presents promising markers for lung cancer diagnosis and prognosis. The purpose of this study was to determine the association between the promoter hypermethylation of multiple genes and 5‑year survival rate in patients with Non‑small cell lung cancer (NSCLC). Materials and Methods: Primary tumor samples (n = 65), corresponding nonmalignant lung tissues (n = 65), and circulating blood were obtained from NSCLC patients who underwent curative surgery. Promoter methylation status in seven genes (RASSF1A, CDH13, MGMT, ESR1, DAPK, SOX1, and HOXA9) was quantified by using bisulfite pyrosequencing. Five‑year survival data were obtained by a clinician. Cox proportional hazards models were used to analyze the associations between gene methylation status and overall patient survival. Results: The 5‑year survival of the patients with SOX1 aberrant tumor methylation was found to be statistically significantly shorter than for those patients without aberrant tumor methylation (P = 0.01). This effect was independent of TNM stage. No significant survival differences were associated with aberrant methylation in other genes tested in either of the two tissue types. Conclusion: Our study shows that SOX1 promoter hypermethylation in NSCLC tumors is significantly associated with inferior survival, showing promise as a useful prognostic biomarker in patients with NSCLC.
KW - 5‑year survival rate
KW - SOX1
KW - methylation
KW - non‑small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=85142376222&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142376222&partnerID=8YFLogxK
U2 - 10.4103/jcrt.JCRT_125_20
DO - 10.4103/jcrt.JCRT_125_20
M3 - Article
C2 - 36412431
AN - SCOPUS:85142376222
SN - 0973-1482
VL - 18
SP - 1692
EP - 1696
JO - Journal of Cancer Research and Therapeutics
JF - Journal of Cancer Research and Therapeutics
IS - 6
ER -